Loading…
Beijing biologics maker known for recombinant nerve growth factor drugs treating neurological injuries and neuropathy.
Beijing biologics maker known for recombinant nerve growth factor drugs treating neurological injuries and neuropathy.
In one line: A small, single-product Chinese biologics maker.
Moat: narrow (IP / patents, regulatory licence). One of few approved nerve-growth-factor biologics in China, protecting near-term market share.
Headquarters: Beijing, China · Employees: 491
Size Staidson (Beijing) Biopharmaceuticals (300204.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.41B, the 1727th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥17.55 on 6 Nov 2026.
Performance Over six months the shares fell 36.5%, against -15.7% for the median peer and -16.4% for the China market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue fell 23.5% over the last twelve months (peer median +17.1%); the operating margin is -51.2% (peer median 10.9%).
Valuation It trades at 585.0× forward earnings against a peer median of 15.2× (most expensive of 11).
Capital Return on invested capital runs 16.3 points below its cost of capital (10.1% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥187M | CN¥219M | CN¥323M | CN¥360M | CN¥542M |
| Revenue growth | — | -32% | -10% | -34% | — |
| Gross profit | CN¥150M | CN¥160M | CN¥246M | CN¥275M | CN¥418M |
| EBITDA | n/a | -CN¥58.9M | -CN¥21.0M | -CN¥340M | -CN¥224M |
| Net income | -CN¥99.5M | -CN¥77.8M | -CN¥145M | -CN¥399M | -CN¥197M |
| Free cash flow | -CN¥187M | -CN¥202M | -CN¥86.7M | -CN¥260M | -CN¥226M |
| Capital expenditure | CN¥113M | CN¥76.6M | CN¥23.5M | CN¥32.2M | CN¥56.5M |
| Total debt | CN¥760,797 | CN¥301M | CN¥42.5M | CN¥41.0M | CN¥29.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300204.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.4% | -6.4% | 2nd lowest of 21 |
| 6-month return | -36.5% | -15.7% | 3rd lowest of 21 |
| Distance from 52-week high | -57.4% | -40.1% | 5th lowest of 21 |
| Revenue growth (TTM) | -23.5% | +17.1% | lowest of 18 |
| Operating margin | -51.2% | 10.9% | 6th lowest of 18 |
| Forward P/E | 585.0× | 15.2× | most expensive of 11 |
| ROIC minus cost of capital | -16.3 pp | -4.1 pp | 6th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.41B | -36% | -24% | -51% | 585.0× | n/a | n/a |
| Anupam Rasayan India ANURAS.NS | India | $1.40B | -15% | +52% | 16% | 45.8× | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.40B | -33% | +27% | 12% | 71.6× | n/a | n/a |
| Mezzion Pharma 140410.KS | South Korea | $1.42B | -29% | +7% | -223% | n/a | n/a | n/a |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.39B | -9% | +9% | -13% | n/a | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.39B | -33% | +70% | -220% | n/a | n/a | n/a |
| Nippon Shinyaku 4516.T | Japan | $1.43B | -30% | +12% | 19% | 7.7× | -17.5% | +7.0% |
| Innoviva INVA | United States | $1.38B | -17% | +18% | 36% | 9.4× | -15.4% | +3.9% |
| Mabwell (Shanghai) Bioscience 688062.SS | China | $1.44B | -38% | +15% | -129% | n/a | n/a | n/a |
| Ocular Therapeutix OCUL | United States | $1.45B | -32% | -8% | -603% | n/a | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.45B | -48% | n/a | n/a | n/a | n/a | n/a |
| Pacira Biosciences PCRX | United States | $1.45B | +57% | +6% | 4% | 11.8× | 14.9% | +11.1% |
| Marksans Pharma MARKSANS.NS | India | $1.45B | +50% | +24% | 20% | 24.2× | 31.6% | +16.6% |
| LB Pharmaceuticals LBRX | United States | $1.36B | +31% | n/a | n/a | n/a | n/a | n/a |
| Damora Therapeutics DMRA | United States | $1.46B | -2% | n/a | n/a | n/a | n/a | n/a |
| Shanghai OPM Biosciences 688293.SS | China | $1.35B | +26% | +133% | 11% | 50.3× | 26.1% | +23.1% |
| Phibro Animal Health PAHC | United States | $1.34B | -18% | +17% | 13% | 9.1× | -7.4% | +12.7% |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.34B | -10% | +256% | -27% | n/a | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.34B | +2% | +8% | 11% | 18.6× | 0.3% | -1.3% |
| Idorsia IDIA.SW | Switzerland | $1.34B | -5% | -5% | -70% | n/a | n/a | n/a |
| Lotus Pharmaceutical 1795.TW | Taiwan | $1.34B | -26% | +49% | 24% | 8.4× | -2.4% | +13.8% |